FRAMINGHAM, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, ...
FRAMINGHAM, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, ...
The July 1 quarterly HCPCS Level II update includes several drug/biological code changes, according to an AAPC release. Effective July 1, the HCPCS Level II code J7184 will be replaced with Q2041 ...
FRAMINGHAM, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical ...